Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder
Biomolecules · 2025
DOI: 10.3390/biom15020306 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Ramisha Khan und 6 weiteren Autor:innen. Beteiligte Einrichtung: IMPACT, Institute for Innovation in Physical and Mental Health and Clinical Translation, School of Medicine, Deakin University, Geelong, VIC 3220, Au…. Hauptthemen laut MEDLINE: Amphetamine-Related Disorders, Methamphetamine, Cognition. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, National Health and Medical Research Council (NHMRC), NHMRC Senior Research Fellowship.
Abstract (Originalsprache)
Methamphetamine use disorder is a pressing global health issue, often accompanied by significant cognitive deficits that impair daily functioning and quality of life and complicate treatment. Emerging evidence highlights the potential role of genetic factors in methamphetamine use disorder, particularly in association with cognitive function. This review examines the key genetic and cognitive dimensions and their interplay in methamphetamine use disorder. There is converging evidence from several studies that genetic polymorphisms in BDNF, FAAH, SLC18A1, and SLC18A2 are associated with protection against or susceptibility to the disorder. In addition, people with methamphetamine use disorder consistently displayed impairments in cognitive flexibility and inhibitory control compared with people without the disorder. These cognitive domains were associated with reactivity to methamphetamine cues that were positively correlated with total years of methamphetamine use history. Emerging research also suggests that inhibitory control is negatively correlated with lower blood FAAH mRNA levels, while cognitive flexibility positively correlates with higher blood SLC18A2 mRNA levels, highlighting how genetic and cognitive dimensions interact in methamphetamine use disorder. We also include some future directions, emphasizing potential personalized therapeutic strategies that integrate genetic and cognitive insights. By drawing attention to the interplay between genes and cognition, we hope to advance our understanding of methamphetamine use disorder and inform the development of targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IMPACT, Institute for Innovation in Physical and Mental Health and Clinical Translation, School of Medicine, Deakin University, Geelong, VIC 3220, Australia.
- Centre for Mental Health, Swinburne University of Technology, Melbourne, VIC 3122, Australia.
- Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.
- Orygen, Melbourne, VIC 3052, Australia.
ORCID-Profile: Alyna Turner, Ken Walder, Alexandre A Guerin, Jee Hyun Kim
Förderung
- Australian Research Council
- National Health and Medical Research Council (NHMRC)
- NHMRC Senior Research Fellowship
- University of Melbourne
Zitieren
APA
Khan, R., Turner, A., Berk, M., Walder, K., Rossell, S., Guerin, A. A., & Kim, J. H. (2025). Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder. Biomolecules. https://doi.org/10.3390/biom15020306
Vancouver
Khan R, Turner A, Berk M, Walder K, Rossell S, Guerin AA, et al. Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder. Biomolecules. 2025. doi:10.3390/biom15020306
BibTeX
@article{Khan2025,
author = {Khan, Ramisha and Turner, Alyna and Berk, Michael and Walder, Ken and Rossell, Susan and Guerin, Alexandre A and Kim, Jee Hyun},
title = {Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15020306}
}
EUVIMED